SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
Rio Tinto Signs Interim Agreement With Yinhawangka Aboriginal Group Over Pilbara Mining Operations 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Azul Airlines Wins Court Approval for $2 Billion Debt Restructuring and New Capital Raise 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
Nomura Expands Alternative Assets Strategy With Focus on Private Debt Acquisitions 
Mizuho Raises Broadcom Price Target to $450 on Surging AI Chip Demand 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Coca-Cola’s Costa Coffee Sale Faces Uncertainty as Talks With TDR Capital Hit Snag 
SK Hynix Considers U.S. ADR Listing to Boost Shareholder Value Amid Rising AI Chip Demand 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Trello Outage Disrupts Users as Access Issues Hit Atlassian’s Work Management Platform 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Heidelberg, Germany, March 14, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that Dr. Adi Hoess, CEO, will present at the Oppenheimer 27th Annual Healthcare Conference on Tuesday, March 21, 2017 at 4:30 a.m. (ET) in New York.
A live webcast of the conference presentation can be accessed through the "Events" section on the "Media" page of the Affimed website at http://www.affimed.com/events.php. A replay of the presentation will be available from Affimed's website for 30 days following the respective conference.
About Affimed N.V.
Affimed (Nasdaq: AFMD) engineers targeted immunotherapies, seeking to cure patients by harnessing the power of innate and adaptive immunity (NK- and T-cells). We are developing single and combination therapies to treat cancers and other life-threatening diseases. For more information, please visit www.affimed.com.
IR Contact:
Caroline Stewart, Head IR
Phone: +1 347394 6793
E-Mail: [email protected] or [email protected]
Media Contact:
Anca Alexandru, Head of Communications, EU IR
Phone: +49 6221 64793341
E-Mail: [email protected]
